🇺🇸 FDA

Company profile · Sponsor

Denali

Denali Therapeutics

DNLI · NYSE biotech SOUTH SAN FRANCISCO, CA, USA
Pipeline
23
Drugs
1
Patents
8

Quick answer

Denali (DNLI) is a biotech company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 23 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker DNLI
Exchange NYSE
Company type biotech
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001714899

Pipeline (23)

Search pipeline →

  1. BIIB122

    Denali

    Parkinson Disease

    phase 3 small molecule active

    2 trials

  2. DNL343

    Denali

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    2 trials

  3. Elaprase 2 mg/ml concentrate for solution for infusion

    Denali

    Mucopolysaccharidosis Type II [MPS II]

    phase 3 small molecule active

    1 trial

  4. tividenofusp alfa

    Denali

    Mucopolysaccharidosis II

    phase 3 small molecule active

    3 trials

  5. -, DNL593 Placebo, Sterile lyophilisate in single-dose glass vials, -, FAMOTIDINE

    Denali

    Frontotemporal Dementia (FTD)

    phase 2 small molecule active

    1 trial

  6. A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants with Hunter Syndrome

    Denali

    Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II])

    phase 2 other active

    1 trial

  7. BIIB122 225 mg

    Denali

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  8. BIIB122, Placebo to BIIB122

    Denali

    Parkinson’s disease

    phase 2 small molecule active

    1 trial

  9. DNL126

    Denali

    Mucopolysaccharidosis Type IIIA

    phase 2 small molecule active

    1 trial

  10. DNL593

    Denali

    Frontotemporal Dementia

    phase 2 small molecule active

    1 trial

  11. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease

    Denali

    Early Alzheimer's Disease

    phase 1 other active

    1 trial

  12. BIIB122 (DNL151)

    Denali

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. DNL151

    Denali

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  14. DNL201

    Denali

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  15. DNL201

    Denali

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  16. DNL343

    Denali

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  17. DNL628

    Denali

    Alzheimer Disease, Early Onset

    phase 1 small molecule active

    1 trial

  18. DNL747

    Denali

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  19. DNL747

    Denali

    Amyotrophic Lateral Sclerosis

    phase 1 small molecule terminated

    1 trial

  20. DNL919

    Denali

    Healthy Participant

    phase 1 small molecule completed

    1 trial

  21. DNL952

    Denali

    Late-onset Pompe Disease

    phase 1 small molecule active

    1 trial

  22. [14C] BIIB122 ([14C] DNL151)

    Denali

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  23. [14C]-DNL343

    Denali

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. tividenofusp alfa-eknm

    AVLAYAH

    POWDER,FOR SOLUTION approved

Patents (8)

Search patents →

  1. US 12378540

    Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12358896

    LRRK2 inhibitors and methods of making and using thereof

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12358928

    Compounds, compositions and methods

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12240902

    Anti-TREM2 antibodies and methods of use thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12180211

    Compounds, compositions and methods

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12162948

    Methods of engineering transferrin receptor binding polypeptides

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12129263

    Kinase inhibitors and uses thereof

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11999750

    Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Denali?

Denali (DNLI) is a biotech company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 23 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Denali sponsor?

We track 23 ClinicalTrials.gov-linked programs for Denali, including BIIB122 and 22 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Denali company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.